TITLE

Synergistic effects of RXRα and PPARγ ligands to inhibit growth in human colon cancer cells--phosphorylated RXRα is a critical target for colon cancer management

AUTHOR(S)
Yamazaki, Kenji; Shimizu, Masahito; Okuno, Masataka; Matsushima-Nishiwaki, Rie; Kanemura, Nobuhiro; Araki, Hiroshi; Tsurumi, Hisashi; Kojima, Soichi; Weinstein, I. Bernard; Moriwaki, Hisataka
PUB. DATE
November 2007
SOURCE
Gut;Nov2007, Vol. 56 Issue 11, p1557
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background and aims: The activation of the peroxisome proliferator-activated receptor γ (PPARγ) that forms heterodimers with retinoid X receptors (RXRs) elicits an antineoplastic effect on colorectal cancer. It was previously reported that the accumulation of the non-functional phosphorylated form of RXRα (p-RXRα interfered with its signalling and promoted the growth of hepatoma cells. In this study the effects of p-RXRα on the ability of RXRα and PPARγ ligands to inhibit growth in colon cancer cells was examined. Methods: The effects of the combination of the PPARγ ligand ciglitazone and the RXRα lignad 9-cis-retinoic acid (RA) on inhibition of cell growth in Caco2 human colon cancer cells which express high levels of p-RXRα protein were examined Results: The RXRα protein was phospholylated and also accumulated in human colon cancer tissue samples as well as human colon cancer cell lines. When the phosphorylation of RXRα was inhibited by the MEK inhibitor PD98059 or by transfection with a point-mutated RXRα, which mimicked the unphosphorylated form, the combination of 9-cisRA and ciglitazone synergistically inhibited the cell growth and induced apoptosis. The combined treatment with these agents also caused a decrease in the expression levels of both cyclo-oxygenase-2 (COX-2) and c-Jun proteins and mRNAs. Reporter assays indicated that this combination induced the transcriptional activity of the peroxisome proliferator-responsive element promoter and also inhibited that of the AP-1 promoter. Conclusion: A malfunction of RXRα due to phosphorylation is associated with colorectal cancer. Therefore, the inhibition of phosphorylation of RXRα and the activation of the RXR-PPARγ heterodimer by their respective ligands may be useful in the chemoprevention and/or treatment of colorectal cancer.
ACCESSION #
27560503

 

Related Articles

  • Effect of crude saponins from Gaultheria trichophylla extract on growth inhibition in human colorectal cancer cells. Alam, Fiaz; Saqib, Qazi Najumus; Waheed, Abdul // Bangladesh Journal of Pharmacology;2015, Vol. 10 Issue 1, p160 

    The genus Gaultheria also comprised of species with reported cytotoxic activities. Current research work was carried out to evaluate G. trichophylla crude extract and respective saponins fraction against human colorectal cancer cell line (Caco-2) based on cell viability assays. Caco-2 cells...

  • Compound K, a Ginsenoside Metabolite, Inhibits Colon Cancer Growth via Multiple Pathways Including p53-p21 Interactions. Zhiyu Zhang; Du, Guang-Jian; Wang, Chong-Zhi; Wen, Xiao-Dong; Calway, Tyler; Zejuan Li; He, Tong-Chuan; Wei Du; Bissonnette, Marc; Musch, Mark W.; Chang, Eugene B.; Yuan, Chun-Su // International Journal of Molecular Sciences;Feb2013, Vol. 14 Issue 2, p2980 

    Compound K (20-O-beta-D-glucopyranosyl-20(S)-protopanaxadiol, CK), an intestinal bacterial metabolite of ginseng protopanaxadiol saponins, has been shown to inhibit cell growth in a variety of cancers. However, the mechanisms are not completely understood, especially in colorectal cancer (CRC)....

  • Nature: Tumor microenvironment helps skin cancer cells resist drug treatment.  // Biomedical Market Newsletter;7/19/2012, Vol. 21, p1 

    The article discusses a study by a team of researchers including Broad Institute, Dana-Farber Cancer Institute, and Massachusetts General Hospital which suggests that normal cells that lie within cancerous cells may supply factors that help cancer cells grow in presence of anti-cancer drugs.

  • Irinotecan Injection.  // AHFS Consumer Medication Information;Feb2017, p1 

    Irinotecan is used alone or in combination with other medications to treat colon or rectal cancer (cancer that begins in the large intestine). Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It works by stopping the growth of cancer cells.

  • Docosahexaenoic fatty acid (DHA) in the regulation of colon cell growth and cell death: A review. Skender, Belma; Vaculova, Alena Hyrslova; Hofmanova, Jirina // Biomedical Papers of the Medical Faculty of Palacky University i;Sep2012, Vol. 156 Issue 3, p186 

    Background. Experimental, epidemiological and clinical data substantiate the beneficial role of n-3 polyunsaturated fatty acids (PUFAs) in preventing inflammation and cancer of the colon. This review covers the unsaturated docosa- hexaenoic fatty acid (DHA), describes some of its important...

  • Anticancer drugs: Pulling the plug on cancer. Kirkpatrick, Peter // Nature Reviews Drug Discovery;Sep2002, Vol. 1 Issue 9, p657 

    Cites the study conducted by Leder and colleagues that identify and characterize the effects f a small molecule that can selectively inhibit the proliferation of a range of cancer cells. Ability to target a difference in the properties of their mitochondria correlated with the overexpression of...

  • Expression of neutrophil gelatinase-associated lipocalin in colorectal neoplastic progression: a marker of malignant potential? McLean, M H; Thomson, A J; Murray, G I; Fyfe, N; Hold, G L; El-Omar, E M // British Journal of Cancer;6/25/2013, Vol. 108 Issue 12, p2537 

    Background:Neutrophil gelatinase-associated lipocalin (NGAL) has a diverse functional repertoire, involved in the innate immune response as well as cell growth and differentiation. Expression has been linked to malignant disease development and progression.Methods:Neutrophil...

  • Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Montagut, Clara; Dalmases, Alba; Bellosillo, Beatriz; Crespo, Marta; Pairet, Silvia; Iglesias, Mar; Salido, Marta; Gallen, Manuel; Marsters, Scot; Tsai, Siao Ping; Minoche, André; Somasekar, Seshagiri; Serrano, Sergi; Himmelbauer, Heinz; Bellmunt, Joaquim; Rovira, Ana; Settleman, Jeff; Bosch, Francesc; Albanell, Joan // Nature Medicine;Feb2012, Vol. 18 Issue 2, p221 

    Antibodies against epidermal growth factor receptor (EGFR)-cetuximab and panitumumab-are widely used to treat colorectal cancer. Unfortunately, patients eventually develop resistance to these agents. We describe an acquired EGFR ectodomain mutation (S492R) that prevents cetuximab binding and...

  • Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo. Cai Xun; Min-Bin Chen; Li Qi; Zhang Tie-Ning; Xue Peng; Li Ning; Chen Zhi-Xiao; Wang Li-Wei // Journal of Experimental & Clinical Cancer Research (17569966);9/6/2015, Vol. 34 Issue 1, p1 

    Background: Colorectal cancer (CRC) is a major health problem in China and around the world. It is one of the leading causes of cancer-related deaths. Research groups are thus searching for novel and more efficient anti-CRC agents. Results: Here we demonstrated that ABC294640, a novel SphK2...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics